Sign up for the QMED & MD+DI Daily newsletter.
A gene-based urine test could provide a more specific diagnosis of prostate cancer than the PSA test. The test, developed by Gen-Probe, examines the PCA3 (prostate cancer gene 3) score. According to a study published in the May issue of Journal of Urology, the PCA3 could be the most successful measure to detect the stage and grade of prostate cancer. It's possible that doctors could use Gen-Probe's test, PROGENSA, to actively monitor tumor growth before aggressive and invasive treatment is explored.
May 9, 2008
1 Min Read
This could be an especially useful tool in cases of older cancer patients, where many doctors opt for a wait-and-see approach. The study also found a connection between the PCA3 score and tumor volume, and that the PCA3 score was the best predictor of tumor volume when compared with other measures.
You May Also Like
BioSig Cuts a Substantial Number of PositionsFeb 20, 2024|2 Min Read
Philips BrightView Imaging System Hit with Class I RecallFeb 20, 2024|2 Min Read
Medtronic Exits Ventilator Market, Raises FY24 OutlookFeb 20, 2024|4 Min Read
Medical Device Suppliers Unite to Form the WCDAFeb 20, 2024